These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 8983882

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of macrolides on ultrastructure of Staphylococcus aureus during postantibiotic phase.
    Watanabe T, Kanno M, Tejima E, Orikasa Y.
    Drugs Exp Clin Res; 1992; 18(3):81-8. PubMed ID: 1425207
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Erythromycin, clarithromycin, and azithromycin: are the differences real?
    Amsden GW.
    Clin Ther; 1996; 18(1):56-72; discussion 55. PubMed ID: 8851453
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues.
    Griesgraber G, Kramer MJ, Elliott RL, Nilius AM, Ewing PJ, Raney PM, Bui MH, Flamm RK, Chu DT, Plattner JJ, Or YS.
    J Med Chem; 1998 May 07; 41(10):1660-70. PubMed ID: 9572891
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S, Iwasawa H, Iino S, Shimada J.
    Jpn J Antibiot; 1997 Oct 07; 50(10):844-53. PubMed ID: 9412874
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro and in vivo antibacterial activity of 9,3"-Di-o-acetyl midecamycin (Mom), a new macrolide antibiotic.
    Kawaharajo K, Sekizawa Y, Inoue M.
    J Antibiot (Tokyo); 1981 Apr 07; 34(4):436-42. PubMed ID: 6974163
    [Abstract] [Full Text] [Related]

  • 37. Use of flurythromycin ethylsuccinate in infections of lower airways due to sensitive germs: multicenter comparative study with clarithromycin.
    Vagliasindi M.
    Int J Clin Pharmacol Ther; 1997 Jun 07; 35(6):245-9. PubMed ID: 9208340
    [Abstract] [Full Text] [Related]

  • 38. Sporeamicin A, a new macrolide antibiotic. III. Biological properties.
    Morishita A, Mutoh N, Ishizawa K, Suzuki T, Yokoiyama S, Yaginuma S.
    J Antibiot (Tokyo); 1992 May 07; 45(5):613-7. PubMed ID: 1624362
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.